High Frequency of Germline TP53 Mutations in a Prospective Adult-Onset Sarcoma Cohort

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Mitchell, Gillian ^a,b   Ballinger, Mandy L ^a,b   Wong, Stephen ^a   Hewitt, Chelsee ^a   James, Paul ^a,b   Young, Mary Anne ^a,b   Cipponi, Arcadi ^a,b   Pang, Tiffany ^a,b   Goode, David L ^a,b   Dobrovic, Alex ^a,b   Thomas, David M ^a,b   Porceddu, Sandro ^a,c   Gattas, Michael ^a,d   Neuhaus, Susan ^a,e   Suthers, Graeme ^a,e   Tattersall, Martin ^a,f   Tucker, Kathy ^a,g   Lewis, Craig ^a,g   Carey Smith, Richard ^a,h  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d Genetics Health Queensland ^*  (Australia)

^e ROYAL ADELAIDE HOSPITAL   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g PRINCE OF WALES HOSPITAL   (Australia)

^h HOLLYWOOD PRIVATE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P53;

ADOLESCENT; ADULT; ADULT ONSET SARCOMA; AGED; ARTICLE; CANCER SURVIVAL; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; EPITHELIUM; FEMALE; GENE DOSAGE; GENE MUTATION; HETEROZYGOTE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PRESCHOOL CHILD; PROSPECTIVE STUDY; SARCOMA; SCHOOL CHILD; TP53 GENE;

ADULT; AGE OF ONSET; BASE SEQUENCE; COHORT STUDIES; FEMALE; GERM-LINE MUTATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PEDIGREE; PROSPECTIVE STUDIES; SARCOMA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84880660114     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069026     Document Type: Article

References (33)

1. Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, et al. (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48: 5358-5362.
2. Birch JM, Blair V, Kelsey AM, Evans DG, Harris M, et al. (1998) Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene 17: 1061-1068.
3. Chompret A, Brugieres L, Ronsin M, Gardes M, Dessarps-Freichey F, et al. (2000) P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 82: 1932-1937.
4. Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, et al. (2001) Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20: 4621-4628.
5. Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, et al. (2003) Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63: 6643-6650.
6. Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, et al. (2009) Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27: 1250-1256.
7. Nichols KE, Malkin D, Garber JE, Fraumeni JF Jr, Li FP, (2001) Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 10: 83-87.
8. Ruijs MW, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, et al. (2010) TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 47: 421-428.
9. Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, et al. (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365: 1769-1778.
10. Villani A, Tabori U, Schiffman J, Shlien A, Beyene J, et al. (2011) Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol 12: 559-567.
11. Bougeard G, Sesboue R, Baert-Desurmont S, Vasseur S, Martin C, et al. (2008) Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 45: 535-538.
12. Toguchida J, Yamaguchi T, Dayton SH, Beauchamp RL, Herrera GE, et al. (1992) Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 326: 1301-1308.
13. Malkin D, Jolly KW, Barbier N, Look AT, Friend SH, et al. (1992) Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 326: 1309-1315.
14. Tabori U, Shlien A, Baskin B, Levitt S, Ray P, et al. (2010) TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. J Clin Oncol 28: 1995-2001.
15. Lalloo F, Varley J, Moran A, Ellis D, O'Dair L, et al. (2006) BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 42: 1143-1150.
16. Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, et al. (2001) An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A 98: 9330-9335.
17. Olivier M, Hollstein M, Hainaut P, (2010) TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2: a001008.
18. Ognjanovic S, Olivier M, Bergemann TL, Hainaut P, (2012) Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Cancer 118: 1387-1396.
19. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622-629.
20. Prochazkova K, Pavlikova K, Minarik M, Sumerauer D, Kodet R, et al. (2009) Somatic TP53 mutation mosaicism in a patient with Li-Fraumeni syndrome. Am J Med Genet A 149A: 206-211.
21. McIntyre JF, Smith-Sorensen B, Friend SH, Kassell J, Borresen AL, et al. (1994) Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol 12: 925-930.
22. Mouchawar J, Korch C, Byers T, Pitts TM, Li E, et al. (2010) Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Cancer Res 70: 4795-4800.
23. Evans DG, Lunt P, Clancy T, Eeles R, (2010) Childhood predictive genetic testing for Li-Fraumeni syndrome. Fam Cancer 9: 65-69.
24. Tischkowitz M, Rosser E, (2004) Inherited cancer in children: practical/ethical problems and challenges. Eur J Cancer 40: 2459-2470.
25. Offit K, Kohut K, Clagett B, Wadsworth EA, Lafaro KJ, et al. (2006) Cancer genetic testing and assisted reproduction. J Clin Oncol 24: 4775-4782.
26. Chompret A, Abel A, Stoppa-Lyonnet D, Brugieres L, Pages S, et al. (2001) Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 38: 43-47.
27. Tinat J, Bougeard G, Baert-Desurmont S, Vasseur S, Martin C, et al. (2009) 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 27: e108-109; author reply e110.
28. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, et al. (1994) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54: 1298-1304.
29. Eeles RA, (1995) Germline mutations in the TP53 gene. Cancer Surv 25: 101-124.
30. Wu L, Patten N, Yamashiro CT, Chui B, (2002) Extraction and amplification of DNA from formalin-fixed, paraffin-embedded tissues. Appl Immunohistochem Mol Morphol 10: 269-274.
31. Krypuy M, Ahmed AA, Etemadmoghadam D, Hyland SJ, DeFazio A, et al. (2007) High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer 7: 168.
32. Kato S, Han SY, Liu W, Otsuka K, Shibata H, et al. (2003) Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 100: 8424-8429.
33. Li J, Lupat R, Amarasinghe KC, Thompson ER, Doyle MA, et al. (2012) CONTRA: copy number analysis for targeted resequencing. Bioinformatics 28: 1307-1313.